Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Causes & Control
Published in: Cancer Causes & Control 4/2011

Open Access 01-04-2011 | Original paper

Variation in folate pathway genes and distal colorectal adenoma risk: a sigmoidoscopy-based case–control study

Authors: A. Joan Levine, Won Lee, Jane C. Figueiredo, David V. Conti, David J. Vandenberg, Brian D. Davis, Christopher K. Edlund, Susanne M. Henning, David Heber, Mariana C. Stern, Robert W. Haile

Published in: Cancer Causes & Control | Issue 4/2011

Login to get access

Abstract

Background

Folate-associated one-carbon metabolism (FOCM) is an important pathway in colorectal neoplasia risk but data on genetic variation in this pathway are largely limited to studies of single SNPs in selected genes.

Methods

We used a comprehensive tagSNP approach to study the association between genetic variation in 11 genes in the FOCM pathway and risk of incident distal colorectal adenomas in a sigmoidoscopy-based case–control study. We included 655 cases (one or more adenomas) and 695 controls (no adenomas) recruited from one of two Kaiser Permanente clinics between 1991 and 1995. We assessed a total of 159 tagSNPs selected using Haploview Tagger as well as selected non-synonymous SNPs. We used unconditional logistic regression to model the association between SNPs and risk of distal adenomas, assuming a log-additive model.

Results

Five SNPs in the SLC19A1 (RFC1) gene: rs1051266 (G80A), rs283895, rs2236484, rs12482346, and rs2838958 were associated with adenoma risk after correction for multiple testing (all corrected p values ≤0.043). The non-synonymous SLC19A1 SNP G80A interacted significantly with the MTHFR C677T genotype (interaction p value = 0.018).

Conclusion

Our data suggest that genetic variation in SLC19A1 may modify the risk of distal colorectal adenoma.
Appendix
Available only for authorised users
Literature
1.
Kim YI (2003) Role of folate in colon cancer development and progression. J Nutr 133:3731S–3739SPubMed
2.
Giovannucci E (2002) Epidemiologic studies of folate and colorectal neoplasia: a review. J Nutr 132:2350S–2355SPubMed
3.
Mason JB, Choi SW (2000) The mechanisms by which folate depletion enhances colorectal carcinogenesis: a unified scheme. Nestle Nutr Workshop Ser Clin Perform Programme 4:87–99; discussion 99–101
4.
Cole BF, Baron JA, Sandler RS, Haile RW, Ahnen DJ, Bresalier RS, McKeown-Eyssen G, Summers RW, Rothstein RI, Burke CA et al (2007) Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. JAMA 297:2351–2359PubMedCrossRef
5.
Song J, Medline A, Mason JB, Gallinger S, Kim YI (2000) Effects of dietary folate on intestinal tumorigenesis in the apcMin mouse. Cancer Res 60:5434–5440PubMed
6.
Song J, Sohn KJ, Medline A, Ash C, Gallinger S, Kim YI (2000) Chemopreventive effects of dietary folate on intestinal polyps in Apc ± Msh2−/− mice. Cancer Res 60:3191–3199PubMed
7.
Nijhout HF, Reed MC, Ulrich CM (2008) Mathematical models of folate-mediated one-carbon metabolism. Vitam Horm 79:45–82PubMedCrossRef
8.
Ulrich CM, Neuhouser M, Liu AY, Boynton A, Gregory JF III, Shane B, James SJ, Reed MC, Nijhout HF (2008) Mathematical modeling of folate metabolism: predicted effects of genetic polymorphisms on mechanisms and biomarkers relevant to carcinogenesis. Cancer Epidemiol Biomarkers Prev 17:1822–1831PubMedCrossRef
9.
Ulrich CM (2005) Nutrigenetics in cancer research–folate metabolism and colorectal cancer. J Nutr 135:2698–2702PubMed
10.
Xu X, Liu AY, Ulrich CM, Chen J (2009) Folate and cancer: epidemiological perspective. Taylor and Francis, New York
11.
Huang Y, Han S, Li Y, Mao Y, Xie Y (2007) Different roles of MTHFR C677T and A1298C polymorphisms in colorectal adenoma and colorectal cancer: a meta-analysis. J Hum Genet 52:73–85PubMedCrossRef
12.
Kono S, Chen K (2005) Genetic polymorphisms of methylenetetrahydrofolate reductase and colorectal cancer and adenoma. Cancer Sci 96:535–542PubMedCrossRef
13.
Hazra A, Wu K, Kraft P, Fuchs CS, Giovannucci EL, Hunter DJ (2007) Twenty-four non-synonymous polymorphisms in the one-carbon metabolic pathway and risk of colorectal adenoma in the Nurses’ Health Study. Carcinogenesis 28:1510–1519PubMedCrossRef
14.
Stern MC, Siegmund KD, Conti DV, Corral R, Haile RW (2006) XRCC1, XRCC3, and XPD polymorphisms as modifiers of the effect of smoking and alcohol on colorectal adenoma risk. Cancer Epidemiol Biomarkers Prev 15:2384–2390PubMedCrossRef
15.
Stern MC, Siegmund KD, Corral R, Haile RW (2005) XRCC1 and XRCC3 polymorphisms and their role as effect modifiers of unsaturated fatty acids and antioxidant intake on colorectal adenomas risk. Cancer Epidemiol Biomarkers Prev 14:609–615PubMedCrossRef
16.
Rimm EB, Giovannucci EL, Stampfer MJ, Colditz GA, Litin LB, Willett WC (1992) Reproducibility and validity of an expanded self-administered semiquantitative food frequency questionnaire among male health professionals. Am J Epidemiol 135:1114–1126; discussion 1127–1136
17.
Stram DO, Hankin JH, Wilkens LR, Pike MC, Monroe KR, Park S, Henderson BE, Nomura AM, Earle ME, Nagamine FS et al (2000) Calibration of the dietary questionnaire for a multiethnic cohort in Hawaii and Los Angeles. Am J Epidemiol 151:358–370PubMed
18.
Bird CL, Swendseid ME, Witte JS, Shikany JM, Hunt IF, Frankl HD, Lee ER, Longnecker MP, Haile RW (1995) Red cell and plasma folate, folate consumption, and the risk of colorectal adenomatous polyps. Cancer Epidemiol Biomarkers Prev 4:709–714PubMed
19.
Kuo K, Still R, Cale S, McDowell I (1997) Standardization (external and internal) of HPLC assay for plasma homocysteine. Clin Chem 43:1653–1655PubMed
20.
Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21:263–265PubMedCrossRef
21.
Shen R, Fan JB, Campbell D, Chang W, Chen J, Doucet D, Yeakley J, Bibikova M, Wickham Garcia E, McBride C et al (2005) High-throughput SNP genotyping on universal bead arrays. Mutat Res 573:70–82PubMedCrossRef
22.
Consortium TIH (2005) A haplotype map of the human genome. Nature 437:1299–1320CrossRef
23.
Levine AJ, Siegmund KD, Ervin CM, Diep A, Lee ER, Frankl HD, Haile RW (2000) The methylenetetrahydrofolate reductase 677C→T polymorphism and distal colorectal adenoma risk. Cancer Epidemiol Biomarkers Prev 9:657–663PubMed
24.
Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJ, den Heijer M, Kluijtmans LA, van den Heuvel LP et al (1995) A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 10:111–113PubMedCrossRef
25.
Li Y, Abecasis GR (2006) Mach 1.0: rapid haplotype reconstruction and missing genotype inference. Am J Hum Genet S79:2290
26.
Conneely KN, Boehnke M (2007) So many correlated tests, so little time! Rapid adjustment of p values for multiple correlated tests. Am J Hum Genet 81:1158–1168CrossRef
27.
Lucock M (2000) Folic acid: nutritional biochemistry, molecular biology, and role in disease processes. Mol Genet Metab 71:121–138PubMedCrossRef
28.
Ma DW, Finnell RH, Davidson LA, Callaway ES, Spiegelstein O, Piedrahita JA, Salbaum JM, Kappen C, Weeks BR, James J et al (2005) Folate transport gene inactivation in mice increases sensitivity to colon carcinogenesis. Cancer Res 65:887–897PubMed
29.
Eklof V, Van Guelpen B, Hultdin J, Johansson I, Hallmans G, Palmqvist R (2008) The reduced folate carrier (RFC1) 80G>A and folate hydrolase 1 (FOLH1) 1561C>T polymorphisms and the risk of colorectal cancer: a nested case-referent study. Scand J Clin Lab Invest 68:393–401PubMedCrossRef
30.
Ulrich CM, Curtin K, Potter JD, Bigler J, Caan B, Slattery ML (2005) Polymorphisms in the reduced folate carrier, thymidylate synthase, or methionine synthase and risk of colon cancer. Cancer Epidemiol Biomarkers Prev 14:2509–2516PubMedCrossRef
31.
Boyapati SM, Bostick RM, McGlynn KA, Fina MF, Roufail WM, Geisinger KR, Hebert JR, Coker A, Wargovich M (2004) Folate intake, MTHFR C677T polymorphism, alcohol consumption, and risk for sporadic colorectal adenoma (United States). Cancer Causes Control 15:493–501PubMedCrossRef
32.
Marugame T, Tsuji E, Kiyohara C, Eguchi H, Oda T, Shinchi K, Kono S (2003) Relation of plasma folate and methylenetetrahydrofolate reductase C677T polymorphism to colorectal adenomas. Int J Epidemiol 32:64–66PubMedCrossRef
33.
Ulrich CM, Kampman E, Bigler J, Schwartz SM, Chen C, Bostick R, Fosdick L, Beresford SA, Yasui Y, Potter JD (1999) Colorectal adenomas and the C677T MTHFR polymorphism: evidence for gene-environment interaction? Cancer Epidemiol Biomarkers Prev 8:659–668PubMed
34.
Ulvik A, Evensen ET, Lien EA, Hoff G, Vollset SE, Majak BM, Ueland PM (2001) Smoking, folate and methylenetetrahydrofolate reductase status as interactive determinants of adenomatous and hyperplastic polyps of colorectum. Am J Med Genet 101:246–254PubMedCrossRef
35.
Chen J, Giovannucci E, Hankinson SE, Ma J, Willett WC, Spiegelman D, Kelsey KT, Hunter DJ (1998) A prospective study of methylenetetrahydrofolate reductase and methionine synthase gene polymorphisms, and risk of colorectal adenoma. Carcinogenesis 19:2129–2132PubMedCrossRef
36.
Giovannucci E, Chen J, Smith-Warner SA, Rimm EB, Fuchs CS, Palomeque C, Willett WC, Hunter DJ (2003) Methylenetetrahydrofolate reductase, alcohol dehydrogenase, diet, and risk of colorectal adenomas. Cancer Epidemiol Biomarkers Prev 12:970–979PubMed
37.
Lightfoot TJ, Barrett JH, Bishop T, Northwood EL, Smith G, Wilkie MJ, Steele RJ, Carey FA, Key TJ, Wolf R et al (2008) Methylene tetrahydrofolate reductase genotype modifies the chemopreventive effect of folate in colorectal adenoma, but not colorectal cancer. Cancer Epidemiol Biomarkers Prev 17:2421–2430PubMedCrossRef
38.
van den Donk M, Buijsse B, van den Berg SW, Ocke MC, Harryvan JL, Nagengast FM, Kok FJ, Kampman E (2005) Dietary intake of folate and riboflavin, MTHFR C677T genotype, and colorectal adenoma risk: a Dutch case–control study. Cancer Epidemiol Biomarkers Prev 14:1562–1566PubMedCrossRef
39.
Mitrou PN, Watson MA, Loktionov AS, Cardwell C, Gunter MJ, Atkin WS, Macklin CP, Cecil T, Bishop TD, Primrose J et al (2006) MTHFR (C677T and A1298C) polymorphisms and risk of sporadic distal colorectal adenoma in the UK flexible sigmoidoscopy screening trial (United Kingdom). Cancer Causes Control 17:793–801PubMedCrossRef
40.
Curtin K, Bigler J, Slattery ML, Caan B, Potter JD, Ulrich CM (2004) MTHFR C677T and A1298C polymorphisms: diet, estrogen, and risk of colon cancer. Cancer Epidemiol Biomarkers Prev 13:285–292PubMedCrossRef
41.
Keku T, Millikan R, Worley K, Winkel S, Eaton A, Biscocho L, Martin C, Sandler R (2002) 5,10-Methylenetetrahydrofolate reductase codon 677 and 1298 polymorphisms and colon cancer in African Americans and whites. Cancer Epidemiol Biomarkers Prev 11:1611–1621PubMed
42.
Matsuo K, Ito H, Wakai K, Hirose K, Saito T, Suzuki T, Kato T, Hirai T, Kanemitsu Y, Hamajima H et al (2005) One-carbon metabolism related gene polymorphisms interact with alcohol drinking to influence the risk of colorectal cancer in Japan. Carcinogenesis 26:2164–2171PubMedCrossRef
43.
Otani T, Iwasaki M, Hanaoka T, Kobayashi M, Ishihara J, Natsukawa S, Shaura K, Koizumi Y, Kasuga Y, Yoshimura K et al (2005) Folate, vitamin B6, vitamin B12, and vitamin B2 intake, genetic polymorphisms of related enzymes, and risk of colorectal cancer in a hospital-based case–control study in Japan. Nutr Cancer 53:42–50PubMedCrossRef
44.
Koushik A, Kraft P, Fuchs CS, Hankinson SE, Willett WC, Giovannucci EL, Hunter DJ (2006) Nonsynonymous polymorphisms in genes in the one-carbon metabolism pathway and associations with colorectal cancer. Cancer Epidemiol Biomarkers Prev 15:2408–2417PubMedCrossRef
45.
Curtin K, Slattery ML, Ulrich CM, Bigler J, Levin TR, Wolff RK, Albertsen H, Potter JD, Samowitz WS (2007) Genetic polymorphisms in one-carbon metabolism: associations with CpG island methylator phenotype (CIMP) in colon cancer and the modifying effects of diet. Carcinogenesis 28:1672–1679PubMedCrossRef
46.
Yin G, Kono S, Toyomura K, Hagiwara T, Nagano J, Mizoue T, Mibu R, Tanaka M, Kakeji Y, Maehara Y et al (2004) Methylenetetrahydrofolate reductase C677T and A1298C polymorphisms and colorectal cancer: the Fukuoka colorectal cancer study. Cancer Sci 95:908–913PubMedCrossRef
47.
Murtaugh MA, Curtin K, Sweeney C, Wolff RK, Holubkov R, Caan BJ, Slattery ML (2007) Dietary intake of folate and co-factors in folate metabolism, MTHFR polymorphisms, and reduced rectal cancer. Cancer Causes Control 18:153–163PubMedCrossRef
48.
Chango A, Emery-Fillon N, de Courcy GP, Lambert D, Pfister M, Rosenblatt DS, Nicolas JP (2000) A polymorphism (80G→A) in the reduced folate carrier gene and its associations with folate status and homocysteinemia. Mol Genet Metab 70:310–315PubMedCrossRef
49.
Devlin AM, Clarke R, Birks J, Evans JG, Halsted CH (2006) Interactions among polymorphisms in folate-metabolizing genes and serum total homocysteine concentrations in a healthy elderly population. Am J Clin Nutr 83:708–713PubMed
50.
Feix A, Fritsche-Polanz R, Kletzmayr J, Vychytil A, Horl WH, Sunder-Plassmann G, Fodinger M (2001) Increased prevalence of combined MTR and MTHFR genotypes among individuals with severely elevated total homocysteine plasma levels. Am J Kidney Dis 38:956–964PubMedCrossRef
51.
Gross M, Friedman G, Eliashar R, Koren-Morag N, Goldschmidt N, Atta IA, Ben-Yehuda A (2006) Impact of methionine synthase gene and methylenetetrahydrofolate reductase gene polymorphisms on the risk of sudden sensorineural hearing loss. Audiol Neurootol 11:287–293PubMedCrossRef
52.
Le Marchand L, Donlon T, Hankin JH, Kolonel LN, Wilkens LR, Seifried A (2002) B-vitamin intake, metabolic genes, and colorectal cancer risk (United States). Cancer Causes Control 13:239–248PubMedCrossRef
53.
Mostowska A, Hozyasz KK, Wojcicki P, Dziegelewska M, Jagodzinski PP (2009) Associations of folate and choline metabolism gene polymorphisms with orofacial clefts. J Med Genet 47:809–815PubMedCrossRef
54.
Terruzzi I, Senesi P, Fermo I, Lattuada G, Luzi L (2007) Are genetic variants of the methyl group metabolism enzymes risk factors predisposing to obesity? J Endocrinol Invest 30:747–753PubMed
Metadata
Title
Variation in folate pathway genes and distal colorectal adenoma risk: a sigmoidoscopy-based case–control study
Authors
A. Joan Levine
Won Lee
Jane C. Figueiredo
David V. Conti
David J. Vandenberg
Brian D. Davis
Christopher K. Edlund
Susanne M. Henning
David Heber
Mariana C. Stern
Robert W. Haile
Publication date
01-04-2011
Publisher
Springer Netherlands
Published in
Cancer Causes & Control / Issue 4/2011
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-011-9726-7

Other articles of this Issue 4/2011

Cancer Causes & Control 4/2011 Go to the issue

Original paper

Postdiagnosis diet quality, the combination of diet quality and recreational physical activity, and prognosis after early-stage breast cancer

Review article

Estrogens in the breast tissue: a systematic review

Original paper

Healthy eating index and ovarian cancer risk

Original paper

Associations of body size and reproductive factors with circulating levels of sex hormones and prolactin in premenopausal Japanese women

Original paper

Abuse victimization and risk of breast cancer in the Black Women’s Health Study

Original paper

Cigarette smoking shortens the survival of patients with low-risk myelodysplastic syndromes
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits